Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics logoAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AIMT
  • CUSIP: N/A
  • Web: www.aimmune.com
Capitalization:
  • Market Cap: $1.1 billion
  • Outstanding Shares: 50,342,000
Average Prices:
  • 50 Day Moving Avg: $19.66
  • 200 Day Moving Avg: $19.92
  • 52 Week Range: $11.40 - $27.31
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.65
  • P/E Growth: 0.19
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.26 per share
  • Price / Book: 4.14
Profitability:
  • EBIDTA: ($91,620,000.00)
  • Return on Equity: -40.99%
  • Return on Assets: -39.03%
Debt:
  • Current Ratio: 24.35%
  • Quick Ratio: 24.35%
Misc:
  • Average Volume: 304,554 shs.
  • Beta: -1.13
  • Short Ratio: 14.81
 
Frequently Asked Questions for Aimmune Therapeutics (NASDAQ:AIMT)

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.05. View Aimmune Therapeutics' Earnings History.

When will Aimmune Therapeutics make its next earnings announcement?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for Aimmune Therapeutics.

Where is Aimmune Therapeutics' stock going? Where will Aimmune Therapeutics' stock price be in 2017?

4 brokerages have issued twelve-month price targets for Aimmune Therapeutics' stock. Their forecasts range from $30.00 to $42.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $36.25 in the next year. View Analyst Ratings for Aimmune Therapeutics.

What are analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (7/11/2017)
  • 2. Piper Jaffray Companies analysts commented, "Today Aimmune reported 4Q16 financial results, ending the quarter with $249M in cash. We think this cash funds the company through at least YE18. By this time, we should have results from its Phase III PALISADE program in peanut allergy and we see compelling efficacy as well as safety here as the key value-creating event for AIMT shares around YE17/early '18. By YE18, we also expect a BLA filing submitted for use in kids and teens. Based on guidance of BLA timing, and assuming the full year for BLA prep, filing and review (despite the BTD status granted to AR101), we're modestly adjusting first US peds/teens sales from 2019 to 2020, resulting in a new PT of $38. Despite this change, we continue to recommend AIMT in advance of 12-month clinical progress including, importantly, PALISADE up-dosing completion around mid'17 which we see as potentially reducing clinical risk for the program." (3/15/2017)

Who are some of Aimmune Therapeutics' key competitors?

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:

  • Mark D. McDade, Independent Chairman of the Board
  • Stephen G. Dilly M.D. Ph.D., President, Chief Executive Officer, Director
  • Eric H. Bjerkholt, Chief Financial Officer
  • Jeffrey H. Knapp, Chief Operating Officer
  • Susan E. Barrowcliffe, Senior Vice President, General Manager of Europe
  • Mary M. Rozenman, Senior Vice President - Strategy and Corporate Development
  • Douglas T. Sheehy J.D., General Counsel, Secretary
  • Sue Barrowcliffe, General Manager of Europe
  • Daniel C. Adelman M.D., Chief Medical Officer
  • Greg Behar, Independent Director

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Who owns Aimmune Therapeutics stock?

Aimmune Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.02%) and Daiwa SB Investments Ltd. (0.01%). Company insiders that own Aimmune Therapeutics stock include Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Longitude Capital Partners Ii,, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.

Who sold Aimmune Therapeutics stock? Who is selling Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC and Daiwa SB Investments Ltd.. Company insiders that have sold Aimmune Therapeutics stock in the last year include Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy Aimmune Therapeutics stock?

Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of Aimmune Therapeutics stock can currently be purchased for approximately $21.76.


MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.25 (66.59% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$38.00LowView Rating Details
2/17/2017WedbushReiterated RatingOutperform$42.00N/AView Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00N/AView Rating Details
8/19/2016Credit Suisse GroupReiterated RatingBuy$35.00N/AView Rating Details
5/16/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
Earnings by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Earnings History by Quarter for Aimmune Therapeutics (NASDAQ AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017($0.64)N/AView Earnings Details
5/8/2017Q1 2017($0.57)($0.52)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.47)($0.55)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.45)($0.53)ViewN/AView Earnings Details
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
11/4/2015Q3 2015($0.24)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
2017 EPS Consensus Estimate: ($2.64)
2018 EPS Consensus Estimate: ($2.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.55)($0.55)($0.55)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.69)($0.69)($0.69)
Q4 20171($0.80)($0.80)($0.80)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.58)($0.58)($0.58)
Q4 20181($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 69.64%
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2017Douglas T. SheehyInsiderSell7,460$21.66$161,583.60View SEC Filing  
7/17/2017Mary M RozenmanInsiderSell14,940$21.44$320,313.60View SEC Filing  
7/5/2017Mary M RozenmanInsiderSell45,060$20.85$939,501.00View SEC Filing  
7/3/2017Susan E BarrowcliffeInsiderSell15,000$20.26$303,900.00View SEC Filing  
6/23/2017Stephen George DillyInsiderSell49,400$20.21$998,374.00View SEC Filing  
5/12/2017Eric BjerkholtCFOBuy5,000$19.84$99,200.00View SEC Filing  
5/10/2017Stephen George DillyInsiderSell600$20.15$12,090.00View SEC Filing  
4/3/2017Warren L DesouzaCFOSell15,000$21.58$323,700.00View SEC Filing  
3/21/2017Warren L DesouzaCFOSell10,000$22.95$229,500.00View SEC Filing  
11/4/2016Mary M RozenmanInsiderSell24,096$17.60$424,089.60View SEC Filing  
10/5/2016Mary M RozenmanInsiderSell25,000$16.80$420,000.00View SEC Filing  
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.00View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aimmune Therapeutics (NASDAQ:AIMT)
Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
Source:
DateHeadline
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Insider Sells $161,583.60 in Stock
www.americanbankingnews.com - July 21 at 7:31 PM
seekingalpha.com logoAimmune Banks On Food Allergies, Study Expected To Show Positive Results
seekingalpha.com - July 20 at 2:56 AM
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 2:43 PM
americanbankingnews.com logoInsider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 14,940 Shares of Stock
www.americanbankingnews.com - July 17 at 7:15 PM
americanbankingnews.com logo-$0.64 Earnings Per Share Expected for Aimmune Therapeutics, Inc. (AIMT) This Quarter
www.americanbankingnews.com - July 13 at 8:13 AM
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%
finance.yahoo.com - July 10 at 3:27 PM
americanbankingnews.com logoAimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Susan E. Barrowcliffe Sells 15,000 Shares
www.americanbankingnews.com - July 6 at 7:40 PM
americanbankingnews.com logoAimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Sells $939,501.00 in Stock
www.americanbankingnews.com - July 6 at 7:22 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Reports Enrollment of 1st Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101
www.streetinsider.com - July 5 at 4:06 PM
finance.yahoo.com logoAimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
finance.yahoo.com - July 5 at 4:06 PM
finance.yahoo.com logoAimmune Therapeutics (AIMT) Shares March Higher, Can It Continue?
finance.yahoo.com - June 30 at 3:45 PM
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Insider Sells $998,374.00 in Stock
www.americanbankingnews.com - June 27 at 7:29 PM
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 23 at 10:06 AM
streetinsider.com logoAimmune Therapeutics (AIMT) Presents European Phase 3 PALISADE Screening Data at EAACI
www.streetinsider.com - June 22 at 12:26 PM
finance.yahoo.com logoDynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6%
finance.yahoo.com - June 21 at 4:12 PM
finance.yahoo.com logoAimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
finance.yahoo.com - June 20 at 3:59 PM
americanbankingnews.com logoZacks: Analysts Expect Aimmune Therapeutics Inc (AIMT) Will Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - June 19 at 9:40 AM
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - June 18 at 8:56 PM
streetinsider.com logoAimmune Therapeutics (AIMT) to Present Data on Peanut Allergy in Europe at EAACI
www.streetinsider.com - June 15 at 5:00 PM
finance.yahoo.com logoAimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
finance.yahoo.com - June 15 at 5:00 PM
americanbankingnews.com logoAimmune Therapeutics, Inc. (AIMT) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - June 13 at 4:40 PM
finance.yahoo.com logoAimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
finance.yahoo.com - June 12 at 4:29 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 9 at 8:21 PM
finance.yahoo.com logoClearwater project targets peanut allergies
finance.yahoo.com - June 8 at 3:51 PM
finance.yahoo.com logoAimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
finance.yahoo.com - June 8 at 3:51 PM
finance.yahoo.com logoAimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
finance.yahoo.com - June 7 at 3:32 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 9:40 AM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 27 at 3:50 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 16 at 8:18 PM
finance.yahoo.com logoWhy These Drug Stocks May Surge
finance.yahoo.com - May 16 at 6:57 AM
americanbankingnews.com logoEric Bjerkholt Acquires 5,000 Shares of Aimmune Therapeutics Inc (AIMT) Stock
www.americanbankingnews.com - May 15 at 7:50 PM
americanbankingnews.com logoInsider Selling: Aimmune Therapeutics Inc (AIMT) Insider Sells 600 Shares of Stock
www.americanbankingnews.com - May 12 at 8:48 PM
reuters.com logoBRIEF-Aimmune Therapeutics enrolls first patient in late-stage trial of its peanut allergy drug
www.reuters.com - May 12 at 3:59 PM
americanbankingnews.com logoWedbush Comments on Aimmune Therapeutics Inc's Q2 2017 Earnings (AIMT)
www.americanbankingnews.com - May 12 at 10:42 AM
americanbankingnews.com logoWedbush Equities Analysts Boost Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - May 11 at 3:58 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Announces Enrollment of First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101
www.streetinsider.com - May 11 at 3:41 PM
finance.yahoo.com logoAimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
finance.yahoo.com - May 11 at 3:41 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Releases Earnings Results
www.americanbankingnews.com - May 9 at 1:38 PM
finance.yahoo.com logoAimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
finance.yahoo.com - May 9 at 9:23 AM
finance.yahoo.com logoAimmune Therapeutics Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:24 PM
marketbeat.com logoAimmune Therapeutics reports 1Q loss
marketbeat.com - May 8 at 4:13 PM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Receiving Somewhat Critical Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 8:58 AM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 12:37 PM
finance.yahoo.com logoBiotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo
finance.yahoo.com - May 1 at 3:26 PM
americanbankingnews.com logo Analysts Anticipate Aimmune Therapeutics Inc (AIMT) Will Announce Earnings of -$0.53 Per Share
www.americanbankingnews.com - May 1 at 1:02 PM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Receives News Sentiment Score of 0.21
www.americanbankingnews.com - April 27 at 9:34 AM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Earning Somewhat Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 24 at 12:15 PM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Given Media Impact Rating of -0.02
www.americanbankingnews.com - April 21 at 9:05 AM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Given Daily Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 18 at 10:51 AM

Social

Chart

Aimmune Therapeutics (AIMT) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff